메뉴 건너뛰기




Volumn 14, Issue 6, 2016, Pages 523-533

Exploring the management of statin intolerant patients: 2016 and beyond

Author keywords

Creatine kinase; Ezetimibe; Intolerance; Muscle symptoms; New onset diabetes; Non statin lipid lowering drugs; Proprotein convertase subtilisin kexin 9 inhibitors; Side effects; Statins; Transaminases

Indexed keywords

ALIROCUMAB; AMINOTRANSFERASE; ATORVASTATIN; BILE ACID SEQUESTRANT; BOCOCIZUMAB; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTIN; COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; BIOLOGICAL MARKER;

EID: 84995611819     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666160226150028     Document Type: Review
Times cited : (9)

References (174)
  • 1
    • 79960205374 scopus 로고    scopus 로고
    • European Society of Cardiology (ESC); European Atherosclerosis Society (EAS)
    • ESC/EAS Guidelines for the management of dyslipidaemias, ** Current ESC/EAS guidelines for the management of dyslipidaemia
    • Catapano AL, Reiner Z, De Backer G, et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46. ** Current ESC/EAS guidelines for the management of dyslipidaemia
    • (2011) Atherosclerosis , vol.217 , pp. 3-46
    • Catapano, A.L.1    Reiner, Z.2    De Backer, G.3
  • 2
    • 84897970506 scopus 로고    scopus 로고
    • American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • ** Current ACC/AHA guidelines for the management of dyslipidaemia
    • Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-45. ** Current ACC/AHA guidelines for the management of dyslipidaemia
    • (2014) Circulation , vol.129 , pp. 1-45
    • Stone, N.J.1    Robinson, J.G.2    Lichtenstein, A.H.3
  • 3
    • 84872712625 scopus 로고    scopus 로고
    • 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    • ** Current guidelines of the Canadian Cardiovascular Society for the management of dyslipidaemia
    • Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29: 151-67. ** Current guidelines of the Canadian Cardiovascular Society for the management of dyslipidaemia
    • (2013) Can J Cardiol , vol.29 , pp. 151-167
    • Anderson, T.J.1    Grégoire, J.2    Hegele, R.A.3
  • 6
    • 84883337835 scopus 로고    scopus 로고
    • Statins for primary prevention of cardiovascular disease: The benefits outweigh the risks
    • Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol 2013; 28: 554-60.
    • (2013) Curr Opin Cardiol , vol.28 , pp. 554-560
    • Minder, C.M.1    Blumenthal, R.S.2    Blaha, M.J.3
  • 7
    • 84883182510 scopus 로고    scopus 로고
    • Statins for primary prevention: Problems with cardiovascular-risk estimation?
    • Reiner Z. Statins for primary prevention: problems with cardiovascular-risk estimation? Nat Rev Cardiol 2013; 10: 547.
    • (2013) Nat Rev Cardiol , vol.10 , pp. 547
    • Reiner, Z.1
  • 8
    • 84891764226 scopus 로고    scopus 로고
    • Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients—a systematic review and meta-analysis
    • Chang YH, Hsieh MC, Wang CY, et al. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients—a systematic review and meta-analysis. Rev Diabet Stud 2013; 10: 157-70.
    • (2013) Rev Diabet Stud , vol.10 , pp. 157-170
    • Chang, Y.H.1    Hsieh, M.C.2    Wang, C.Y.3
  • 9
    • 84925884366 scopus 로고    scopus 로고
    • The role of statins in the treatment of type 2 diabetes mellitus: An update
    • Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20: 3665-74.
    • (2014) Curr Pharm Des , vol.20 , pp. 3665-3674
    • Katsiki, N.1    Athyros, V.G.2    Karagiannis, A.3    Mikhailidis, D.P.4
  • 10
    • 84930860402 scopus 로고    scopus 로고
    • Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update
    • Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
    • (2015) World J Gastroenterol , vol.21 , pp. 6820-6834
    • Athyros, V.G.1    Tziomalos, K.2    Katsiki, N.3
  • 11
    • 84933523805 scopus 로고    scopus 로고
    • Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
    • Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 2015; 16: 1449-61.
    • (2015) Expert Opin Pharmacother , vol.16 , pp. 1449-1461
    • Athyros, V.G.1    Katsiki, N.2    Karagiannis, A.3    Mikhailidis, D.P.4
  • 13
    • 84892384634 scopus 로고    scopus 로고
    • Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: A systematic review and meta-analysis of randomized clinical trials
    • Zhang X, Xiang C, Zhou YH, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC CardiovascDisord 2014; 14: 19.
    • (2014) BMC Cardiovascdisord , vol.14 , pp. 19
    • Zhang, X.1    Xiang, C.2    Zhou, Y.H.3
  • 14
    • 84942772639 scopus 로고    scopus 로고
    • HMG CoA reductase inhibitors (Statins) for people with chronic kidney disease not requiring dialysis
    • Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; 5: CD007784.
    • (2014) Cochrane Database Syst Rev , vol.5
    • Palmer, S.C.1    Navaneethan, S.D.2    Craig, J.C.3
  • 16
    • 84933526603 scopus 로고    scopus 로고
    • Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
    • Danninger K, Hoppe UC, Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis 2014; 17: 606-11.
    • (2014) Int J Rheum Dis , vol.17 , pp. 606-611
    • Danninger, K.1    Hoppe, U.C.2    Pieringer, H.3
  • 17
    • 84881329514 scopus 로고    scopus 로고
    • Statin therapy and new-onset diabetes: Molecular mechanisms and clinical relevance
    • Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19: 4904-12.
    • (2013) Curr Pharm Des , vol.19 , pp. 4904-4912
    • Banach, M.1    Malodobra-Mazur, M.2    Gluba, A.3
  • 18
    • 84865147415 scopus 로고    scopus 로고
    • Pharmacotherapy: Statins and newonset diabetesmellitus--a matter for debate
    • Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and newonset diabetesmellitus--a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 133-134
    • Athyros, V.G.1    Mikhailidis, D.P.2
  • 19
    • 84923653355 scopus 로고    scopus 로고
    • New-onset diabetes and statins: Throw the bath water out, but, please, keep the baby!
    • * A recent comment on statin-related NOD
    • Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64: 471-5. * A recent comment on statin-related NOD
    • (2015) Metabolism , vol.64 , pp. 471-475
    • Katsiki, N.1    Rizzo, M.2    Mikhailidis, D.P.3    Mantzoros, C.S.4
  • 20
    • 84964691274 scopus 로고    scopus 로고
    • Statin tolerability: In defence of placebocontrolled trials
    • Aug 28. pii: 2047487315602861. [Epub ahead of print]
    • Tobert JA, Newman CB. Statin tolerability: In defence of placebocontrolled trials. Eur J PrevCardiol 2015 Aug 28. pii: 2047487315602861. [Epub ahead of print]
    • (2015) Eur J Prevcardiol
    • Tobert, J.A.1    Newman, C.B.2
  • 21
    • 84921513738 scopus 로고    scopus 로고
    • Statin treatment non-adherence and discontinuation: Clinical implications and potential solutions
    • Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr PharmDes 2014; 20: 6314-24.
    • (2014) Curr Pharmdes , vol.20 , pp. 6314-6324
    • Phan, K.1    Gomez, Y.H.2    Elbaz, L.3    Daskalopoulou, S.S.4
  • 22
    • 84899883299 scopus 로고    scopus 로고
    • The National Lipid AssociationStatin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014update
    • Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid AssociationStatin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014update. J ClinLipidol 2014; 8: S72-81.
    • (2014) J Clinlipidol , vol.8 , pp. S72-S81
    • Guyton, J.R.1    Bays, H.E.2    Grundy, S.M.3    Jacobson, T.A.4
  • 23
    • 84899893293 scopus 로고    scopus 로고
    • The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update
    • ** Current guidelines for statin intolerance
    • Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J ClinLipidol 2014; 8: S58-71. ** Current guidelines for statin intolerance
    • (2014) J Clinlipidol , vol.8 , pp. S58-S71
    • Rosenson, R.S.1    Baker, S.K.2    Jacobson, T.A.3
  • 24
    • 84888237339 scopus 로고    scopus 로고
    • Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update
    • Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29: 1553-68.
    • (2013) Can J Cardiol , vol.29 , pp. 1553-1568
    • Mancini, G.B.1    Tashakkor, A.Y.2    Baker, S.3
  • 25
    • 84927742065 scopus 로고    scopus 로고
    • European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
    • Current guidelines for statin intolerance
    • Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-22. Current guidelines for statin intolerance
    • (2015) Eur Heart J , vol.36 , pp. 1012-1022
    • Stroes, E.S.1    Thompson, P.D.2    Corsini, A.3
  • 26
    • 84924981752 scopus 로고    scopus 로고
    • Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel
    • ** Current guidelines for statin intolerance
    • Banach M, Rizzo M, Toth PP, et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23. ** Current guidelines for statin intolerance
    • (2015) Arch Med Sci , vol.11 , pp. 1-23
    • Banach, M.1    Rizzo, M.2    Toth, P.P.3
  • 27
    • 84925847173 scopus 로고    scopus 로고
    • Adverse effects of statins-myths and reality
    • Simic I, Reiner Z. Adverse effects of statins-myths and reality. Curr Pharm Des 2015; 21: 1220-6.
    • (2015) Curr Pharm Des , vol.21 , pp. 1220-1226
    • Simic, I.1    Reiner, Z.2
  • 28
    • 84994009625 scopus 로고    scopus 로고
    • Statin Useand the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study)
    • Dec 2. [Epub ahead of print]
    • Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA. Statin Useand the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). Am J Cardiol 2015 Dec 2. [Epub ahead of print]
    • (2015) Am J Cardiol
    • Acharya, T.1    Huang, J.2    Tringali, S.3    Frei, C.R.4    Mortensen, E.M.5    Mansi, I.A.6
  • 29
    • 84937734258 scopus 로고    scopus 로고
    • Preoperative Statin Therapy and RenalOutcomes After Cardiac Surgery: A Meta-analysis and Metaregression of 59, 771 Patients
    • Wang J, Gu C, Gao M, et al. Preoperative Statin Therapy and RenalOutcomes After Cardiac Surgery: A Meta-analysis and Metaregression of 59, 771 Patients. Can J Cardiol 2015; 31: 1051-60.
    • (2015) Can J Cardiol , vol.31 , pp. 1051-1060
    • Wang, J.1    Gu, C.2    Gao, M.3
  • 30
    • 84908066776 scopus 로고    scopus 로고
    • Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography
    • Ukaigwe A, Karmacharya P, Mahmood M, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol 2014; 114: 1295-302.
    • (2014) Am J Cardiol , vol.114 , pp. 1295-1302
    • Ukaigwe, A.1    Karmacharya, P.2    Mahmood, M.3
  • 31
    • 84923384596 scopus 로고    scopus 로고
    • Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention
    • Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr Med Res Opin 2015; 31: 191-5.
    • (2015) Curr Med Res Opin , vol.31 , pp. 191-195
    • Athyros, V.G.1    Katsiki, N.2    Karagiannis, A.3    Mikhailidis, D.P.4
  • 33
    • 84900337040 scopus 로고    scopus 로고
    • Treatment and impact ofdyslipidemia in diabetic nephropathy
    • Toyama T, Shimizu M, Furuichi K, et al. Treatment and impact ofdyslipidemia in diabetic nephropathy. ClinExpNephrol 2014; 18: 201-5.
    • (2014) Clinexpnephrol , vol.18 , pp. 201-205
    • Toyama, T.1    Shimizu, M.2    Furuichi, K.3
  • 34
    • 79960430739 scopus 로고    scopus 로고
    • Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study
    • Athyros VG, Karagiannis A, Ganotakis ES, et al.; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
    • (2011) Curr Med Res Opin , vol.27 , pp. 1659-1668
    • Athyros, V.G.1    Karagiannis, A.2    Ganotakis, E.S.3
  • 35
    • 33846023704 scopus 로고    scopus 로고
    • Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study
    • Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
    • (2007) Nephrol Dial Transplant , vol.22 , pp. 118-127
    • Athyros, V.G.1    Mikhailidis, D.P.2    Liberopoulos, E.N.3
  • 36
    • 84897018134 scopus 로고    scopus 로고
    • Statins in chronic kidney disease: Cardiovascular risk and kidney function
    • Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med 2014; 126: 29-36.
    • (2014) Postgrad Med , vol.126 , pp. 29-36
    • Deedwania, P.C.1
  • 37
    • 41549159287 scopus 로고    scopus 로고
    • TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study
    • Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J AmCollCardiol 2008; 51: 1448-54.
    • (2008) J Amcollcardiol , vol.51 , pp. 1448-1454
    • Shepherd, J.1    Kastelein, J.J.2    Bittner, V.3
  • 38
    • 84883771761 scopus 로고    scopus 로고
    • Statins are associated with reduced risk of gastric cancer: A systematic review and meta-analysis
    • Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1721-30.
    • (2013) Ann Oncol , vol.24 , pp. 1721-1730
    • Singh, P.P.1    Singh, S.2
  • 39
    • 84881491358 scopus 로고    scopus 로고
    • Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis
    • Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-32.
    • (2013) Gastroenterology , vol.144 , pp. 323-332
    • Singh, S.1    Singh, P.P.2    Singh, A.G.3
  • 40
    • 84941253605 scopus 로고    scopus 로고
    • Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review andMeta-Analysis
    • Ling Y, Yang L, Huang H, et al. Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review andMeta-Analysis. Medicine (Baltimore) 2015; 94: e908.
    • (2015) Medicine (Baltimore) , vol.94
    • Ling, Y.1    Yang, L.2    Huang, H.3
  • 41
    • 84862492891 scopus 로고    scopus 로고
    • Statin use and risk of pancreatic cancer: A meta-analysis
    • Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control2012; 23: 1099-111.
    • Cancer Causes Control2012 , vol.23 , pp. 1099-1111
    • Cui, X.1    Xie, Y.2    Chen, M.3
  • 42
    • 84874545071 scopus 로고    scopus 로고
    • Statins and the risk of lung cancer: A meta-analysis
    • Tan M, Song X, Zhang G, et al. Statins and the risk of lung cancer: a meta-analysis. PLoS One 2013; 8: e57349.
    • (2013) Plos One , vol.8
    • Tan, M.1    Song, X.2    Zhang, G.3
  • 43
    • 84865144986 scopus 로고    scopus 로고
    • Statin use and risk of breast cancer: A meta-analysis of observational studies
    • Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135: 261-9.
    • (2012) Breast Cancer Res Treat , vol.135 , pp. 261-269
    • Undela, K.1    Srikanth, V.2    Bansal, D.3
  • 44
    • 84876472135 scopus 로고    scopus 로고
    • Statin use and risk of bladder cancer: A meta-analysis
    • Zhang XL, Geng J, Zhang XP, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 2013; 24: 769-76.
    • (2013) Cancer Causes Control , vol.24 , pp. 769-776
    • Zhang, X.L.1    Geng, J.2    Zhang, X.P.3
  • 45
    • 84894471681 scopus 로고    scopus 로고
    • Statin use and risk of kidney cancer: A meta-analysis of observational studies and randomized trials
    • Zhang XL, Liu M, Qian J, et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J ClinPharmacol 2014; 77: 458-65.
    • (2014) Br J Clinpharmacol , vol.77 , pp. 458-465
    • Zhang, X.L.1    Liu, M.2    Qian, J.3
  • 46
    • 84876826457 scopus 로고    scopus 로고
    • Association between statin usage and prostate cancer prevention: A refined meta-analysis based on literature from the years 2005-2010
    • Zhang Y, Zang T. Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010. Urol Int 2013; 90: 259-62.
    • (2013) Urol Int , vol.90 , pp. 259-262
    • Zhang, Y.1    Zang, T.2
  • 47
    • 84921669806 scopus 로고    scopus 로고
    • Statins are potential anti cancerous agents (Review)
    • Altwairgi AK. Statins are potential anti cancerous agents (review). Oncol Rep 2015; 33: 1019-39.
    • (2015) Oncol Rep , vol.33 , pp. 1019-1039
    • Altwairgi, A.K.1
  • 48
    • 84896824167 scopus 로고    scopus 로고
    • Neuropsychiatric adverse eventsassociated with statins: Epidemiology, pathophysiology, prevention andmanagement
    • Tuccori M, Montagnani S, Mantarro S, et al. Neuropsychiatric adverse eventsassociated with statins: epidemiology, pathophysiology, prevention andmanagement. CNS Drugs 2014; 28: 249-72.
    • (2014) CNS Drugs , vol.28 , pp. 249-272
    • Tuccori, M.1    Montagnani, S.2    Mantarro, S.3
  • 49
    • 84908356833 scopus 로고    scopus 로고
    • Regarding long-term statin therapy: Are we trading stronger hearts for weaker brains?
    • Goldstein MR, Mascitelli L. Regarding long-term statin therapy: are we trading stronger hearts for weaker brains? Med Hypotheses 2014; 83: 346-51.
    • (2014) Med Hypotheses , vol.83 , pp. 346-351
    • Goldstein, M.R.1    Mascitelli, L.2
  • 50
    • 84903301576 scopus 로고    scopus 로고
    • Statins in nervous systemassociated diseases: Angels or devils?
    • Lei Q, Peng WN, You H, Hu ZP, Lu W. Statins in nervous systemassociated diseases: angels or devils? Pharmazie 2014; 69: 448-54.
    • (2014) Pharmazie , vol.69 , pp. 448-454
    • Lei, Q.1    Peng, W.N.2    You, H.3    Hu, Z.P.4    Lu, W.5
  • 52
    • 84901501976 scopus 로고    scopus 로고
    • Cognitive effects of statin medications
    • Kelley BJ, Glasser S. Cognitive effects of statin medications. CNS Drugs 2014; 28: 411-9.
    • (2014) CNS Drugs , vol.28 , pp. 411-419
    • Kelley, B.J.1    Glasser, S.2
  • 53
    • 84888265005 scopus 로고    scopus 로고
    • Statins and cognitive function: A systematic review
    • Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688-97.
    • (2013) Ann Intern Med , vol.159 , pp. 688-697
    • Richardson, K.1    Schoen, M.2    French, B.3
  • 54
    • 84888861145 scopus 로고    scopus 로고
    • Statins and cognition: A systematic review and meta-analysis of short-and long-term cognitive effects
    • Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013; 88: 1213-21.
    • (2013) Mayo Clin Proc , vol.88 , pp. 1213-1221
    • Swiger, K.J.1    Manalac, R.J.2    Blumenthal, R.S.3
  • 55
    • 84885918484 scopus 로고    scopus 로고
    • Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies
    • Song Y, Nie H, Xu Y, et al. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr-GerontolInt 2013; 13: 817-24.
    • (2013) Geriatr-Gerontolint , vol.13 , pp. 817-824
    • Song, Y.1    Nie, H.2    Xu, Y.3
  • 56
    • 84875805775 scopus 로고    scopus 로고
    • Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding
    • Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 2013; 22: 345-58.
    • (2013) Pharmacoepidemiol Drug Saf , vol.22 , pp. 345-358
    • Wong, W.B.1    Lin, V.W.2    Boudreau, D.3    Devine, E.B.4
  • 58
    • 78649890465 scopus 로고    scopus 로고
    • GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis
    • Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
    • (2010) Lancet , vol.376 , pp. 1916-1922
    • Athyros, V.G.1    Tziomalos, K.2    Gossios, T.D.3
  • 59
    • 84936806639 scopus 로고    scopus 로고
    • Resolution of nonalcoholic steatohepatitis by rosuvastatin mono therapy in patients with metabolic syndrome
    • Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of nonalcoholic steatohepatitis by rosuvastatin mono therapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
    • (2015) World J Gastroenterol , vol.21 , pp. 7860-7868
    • Kargiotis, K.1    Athyros, V.G.2    Giouleme, O.3
  • 60
    • 84930482185 scopus 로고    scopus 로고
    • Statins and liver disease: From concern to 'wonder' drugs?
    • Bosch J, Forns X. Therapy. Statins and liver disease: from concern to 'wonder' drugs? Nat Rev GastroenterolHepatol 2015; 12: 320-1.
    • (2015) Nat Rev Gastroenterolhepatol , vol.12 , pp. 320-321
    • Bosch, J.1    Therapy, F.X.2
  • 61
    • 84939268765 scopus 로고    scopus 로고
    • Statin use and nonalcoholic steatohepatitis in at risk individuals
    • * A recent study reporting statin-related benefits on liver dysfunction
    • Dongiovanni P, Petta S, Mannisto V, et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12. * A recent study reporting statin-related benefits on liver dysfunction
    • (2015) J Hepatol , vol.63 , pp. 705-712
    • Dongiovanni, P.1    Petta, S.2    Mannisto, V.3
  • 62
    • 34249342305 scopus 로고    scopus 로고
    • Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study
    • Ekstedt M, Franzén LE, Mathiesen UL, et al. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-41.
    • (2007) J Hepatol , vol.47 , pp. 135-141
    • Ekstedt, M.1    Franzén, L.E.2    Mathiesen, U.L.3
  • 63
    • 84894257853 scopus 로고    scopus 로고
    • Clinical approaches to non-alcoholic fatty liver disease
    • Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1712-23.
    • (2014) World J Gastroenterol , vol.20 , pp. 1712-1723
    • Schwenger, K.J.1    Allard, J.P.2
  • 64
    • 84886254094 scopus 로고    scopus 로고
    • IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels
    • Tikkanen MJ, Fayyad R, Faergeman O, et al.; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
    • (2013) Int J Cardiol , vol.168 , pp. 3846-3852
    • Tikkanen, M.J.1    Fayyad, R.2    Faergeman, O.3
  • 65
    • 84899810207 scopus 로고    scopus 로고
    • The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update
    • Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J ClinLipidol 2014; 8: S47-57.
    • (2014) J Clinlipidol , vol.8 , pp. S47-S57
    • Bays, H.1    Cohen, D.E.2    Chalasani, N.3    Harrison, S.A.4
  • 66
    • 84861543083 scopus 로고    scopus 로고
    • The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, Ameri can College of Gastroenterology, and the American Gastroenterological Association
    • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, Ameri can College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
    • (2012) Hepatology , vol.55 , pp. 2005-2023
    • Chalasani, N.1    Younossi, Z.2    Lavine, J.E.3
  • 67
    • 84875850647 scopus 로고    scopus 로고
    • Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
    • Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013; 111: 1123-30.
    • (2013) Am J Cardiol , vol.111 , pp. 1123-1130
    • Navarese, E.P.1    Buffon, A.2    Andreotti, F.3
  • 68
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis
    • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-64.
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 69
    • 84921493092 scopus 로고    scopus 로고
    • Kuchenbaecker KB, et al.HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials
    • Swerdlow DI, Preiss D, Kuchenbaecker KB, et al.HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385 (9965): 351-61.
    • (2015) Lancet , vol.385 , Issue.9965 , pp. 351-361
    • Swerdlow, D.I.1    Preiss, D.2
  • 70
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 71
    • 84864861863 scopus 로고    scopus 로고
    • Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial
    • Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-71.
    • (2012) Lancet , vol.380 , pp. 565-571
    • Ridker, P.M.1    Pradhan, A.2    Macfadyen, J.G.3
  • 72
    • 84866733914 scopus 로고    scopus 로고
    • Statins, risk of diabetes, and implications on outcomes in the general population
    • Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am CollCardiol 2012; 60: 1231-8.
    • (2012) J am Collcardiol , vol.60 , pp. 1231-1238
    • Wang, K.L.1    Liu, C.J.2    Chao, T.F.3
  • 73
    • 84897031074 scopus 로고    scopus 로고
    • Cardiovascular drugs that increase the risk of new onset diabetes
    • Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new onset diabetes. Am Heart J 2014; 167: 421-8.
    • (2014) Am Heart J , vol.167 , pp. 421-428
    • Ong, K.L.1    Barter, P.J.2    Waters, D.D.3
  • 74
    • 84861869259 scopus 로고    scopus 로고
    • Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: A post hoc ATTEMPT analysis
    • Athyros VG, Elisaf MS, Alexandrides T, et al.; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012; 63: 358-66.
    • (2012) Angiology , vol.63 , pp. 358-366
    • Athyros, V.G.1    Elisaf, M.S.2    Alexandrides, T.3
  • 75
    • 85027957106 scopus 로고    scopus 로고
    • Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications
    • Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014; 28: 361-77.
    • (2014) Cardiovasc Drugs Ther , vol.28 , pp. 361-377
    • Zafrir, B.1    Jain, M.2
  • 76
    • 84936817948 scopus 로고    scopus 로고
    • Effect of pitavastatin on glucose, HbA1c and incident diabetes: A metaanalysis of randomized controlled clinical trials in individuals without diabetes
    • Vallejo-Vaz AJ, KondapallySeshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A metaanalysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015; 241: 409-18.
    • (2015) Atherosclerosis , vol.241 , pp. 409-418
    • Vallejo-Vaz, A.J.1    Kondapallyseshasai, S.R.2    Kurogi, K.3
  • 77
    • 84899092930 scopus 로고    scopus 로고
    • Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAILUS studies
    • Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAILUS studies. Curr Med Res Opin 2014; 30: 775-84.
    • (2014) Curr Med Res Opin , vol.30 , pp. 775-784
    • Chapman, M.J.1    Orsoni, A.2    Robillard, P.3
  • 78
    • 84944725737 scopus 로고    scopus 로고
    • Statin Intolerance: The Clinician's Perspective
    • Stulc T, Ce_ka R, Gotto AM Jr. Statin Intolerance: the Clinician's Perspective. Curr Atheroscler Rep 2015; 17: 69.
    • (2015) Curr Atheroscler Rep , vol.17 , pp. 69
    • Stulc, T.1    Ce-Ka, R.2    Gotto, A.M.3
  • 79
    • 84875200123 scopus 로고    scopus 로고
    • Intermittent nondaily dosing strategies inpatients with previous statin-induced myopathy
    • Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies inpatients with previous statin-induced myopathy. Ann Pharmacother 2013; 47: 398-404.
    • (2013) Ann Pharmacother , vol.47 , pp. 398-404
    • Keating, A.J.1    Campbell, K.B.2    Guyton, J.R.3
  • 81
    • 82955203309 scopus 로고    scopus 로고
    • Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers
    • Li JJ, Yang P, Liu J, et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. ClinChimActa 2012; 413: 139-42.
    • (2012) Clinchimacta , vol.413 , pp. 139-142
    • Li, J.J.1    Yang, P.2    Liu, J.3
  • 82
    • 59549099998 scopus 로고    scopus 로고
    • The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and highsensitive Creactive protein levels
    • Kele_ T, AkarBayram N, Kayhan T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and highsensitive Creactive protein levels. AnadoluKardiyolDerg 2008; 8: 407-12.
    • (2008) Anadolukardiyolderg , vol.8 , pp. 407-412
    • Kele, T.1    Akarbayram, N.2    Kayhan, T.3
  • 83
    • 0036708211 scopus 로고    scopus 로고
    • Daily dosing versus alternate-day dosing of simvastatinin patients with hypercholesterolemia
    • Copher HR, Stewart RD. Daily dosing versus alternate-day dosing of simvastatinin patients with hypercholesterolemia. Pharmacotherapy 2002; 22: 1110-6.
    • (2002) Pharmacotherapy , vol.22 , pp. 1110-1116
    • Copher, H.R.1    Stewart, R.D.2
  • 84
    • 79960831385 scopus 로고    scopus 로고
    • Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance
    • Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J ClinLipidol 2011; 5: 308-15.
    • (2011) J Clinlipidol , vol.5 , pp. 308-315
    • Kennedy, S.P.1    Barnas, G.P.2    Schmidt, M.J.3
  • 85
    • 84858222560 scopus 로고    scopus 로고
    • Daily and intermittent rosuvastatin 5_mg therapy in statin intolerant patients: An observational study
    • Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5_mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012; 28: 371-8.
    • (2012) Curr Med Res Opin , vol.28 , pp. 371-378
    • Meek, C.1    Wierzbicki, A.S.2    Jewkes, C.3
  • 86
    • 84903170344 scopus 로고    scopus 로고
    • American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines
    • Eckel RH, Jakicic JM, Ard JD, et al.; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2014; 63: 2960-84.
    • (2014) J am Collcardiol , vol.63 , pp. 2960-2984
    • Eckel, R.H.1    Jakicic, J.M.2    Ard, J.D.3
  • 87
    • 84949191337 scopus 로고    scopus 로고
    • The Interaction between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy
    • Deichmann RE, Lavie CJ, Asher T, DiNicolantonio JJ, O'Keefe JH, Thompson PD. The Interaction between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy. Ochsner J 2015; 15: 429-37.
    • (2015) Ochsner J , vol.15 , pp. 429-437
    • Deichmann, R.E.1    Lavie, C.J.2    Asher, T.3    Dinicolantonio, J.J.4    O'keefe, J.H.5    Thompson, P.D.6
  • 88
    • 84916238750 scopus 로고    scopus 로고
    • Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statinassociatedmyalgia-a systematic review and meta-analysis of 7 studies with 2420 patients
    • Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statinassociatedmyalgia-a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015; 178: 111-6.
    • (2015) Int J Cardiol , vol.178 , pp. 111-116
    • Michalska-Kasiczak, M.1    Sahebkar, A.2    Mikhailidis, D.P.3
  • 89
    • 84912083886 scopus 로고    scopus 로고
    • Vitamin D status modifies the association between statin use and musculoskeletal pain: A population based study
    • Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2015; 238: 77-82.
    • (2015) Atherosclerosis , vol.238 , pp. 77-82
    • Morioka, T.Y.1    Lee, A.J.2    Bertisch, S.3    Buettner, C.4
  • 90
    • 84925445316 scopus 로고    scopus 로고
    • StatinIntolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in MostCases be Safely Resolved by Vitamin D Supplementation
    • Khayznikov M, Hemachrandra K, Pandit R, et al. StatinIntolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in MostCases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci 2015; 7: 86-93.
    • (2015) N am J Med Sci , vol.7 , pp. 86-93
    • Khayznikov, M.1    Hemachrandra, K.2    Pandit, R.3
  • 91
    • 84929358911 scopus 로고    scopus 로고
    • Links between Vitamin D Deficiency and Cardiovascular Diseases
    • Mozos I, Marginean O. Links between Vitamin D Deficiency and Cardiovascular Diseases. BiomedRes Int 2015; 2015: 109275.
    • (2015) Biomedres Int , pp. 2015
    • Mozos, I.1    Marginean, O.2
  • 92
    • 84897969679 scopus 로고    scopus 로고
    • Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomized intervention studies
    • Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomized intervention studies. BMJ 2014; 348: g1903.
    • (2014) BMJ , vol.g1903 , pp. 348
    • Chowdhury, R.1    Kunutsor, S.2    Vitezova, A.3
  • 93
    • 79952021197 scopus 로고    scopus 로고
    • STATIN-D study: Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxy vitamin D
    • Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxy vitamin D. CardiovascTher 2011; 29: 146-52.
    • (2011) Cardiovascther , vol.29 , pp. 146-152
    • Ertugrul, D.T.1    Yavuz, B.2    Cil, H.3
  • 94
    • 84879234697 scopus 로고    scopus 로고
    • Effect of simvastatin/ ezetimibe 10/10 mg versus simvastatin 40 mg on serumvitamin D levels
    • Liberopoulos EN, Makariou SE, Moutzouri E, et al. Effect of simvastatin/ ezetimibe 10/10 mg versus simvastatin 40 mg on serumvitamin D levels. J CardiovascPharmacolTher 2013; 18: 229-33.
    • (2013) J Cardiovascpharmacolther , vol.18 , pp. 229-233
    • Liberopoulos, E.N.1    Makariou, S.E.2    Moutzouri, E.3
  • 95
    • 33947608004 scopus 로고    scopus 로고
    • Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease
    • Pérez-Castrillón JL, Vega G, Abad L, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-5.
    • (2007) Am J Cardiol , vol.99 , pp. 903-905
    • Pérez-Castrillón, J.L.1    Vega, G.2    Abad, L.3
  • 96
    • 84906708202 scopus 로고    scopus 로고
    • Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
    • Anagnostis P, Adamidou F, Slavakis A, et al. Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovasc Med J 2014; 8: 55-60.
    • (2014) Open Cardiovasc Med J , vol.8 , pp. 55-60
    • Anagnostis, P.1    Adamidou, F.2    Slavakis, A.3
  • 97
    • 77954768612 scopus 로고    scopus 로고
    • Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: Results from a randomised, controlled trial
    • Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010; 2010: 957174.
    • (2010) Int J Endocrinol , vol.2010
    • Rejnmark, L.1    Vestergaard, P.2    Heickendorff, L.3    Mosekilde, L.4
  • 98
    • 84938084844 scopus 로고    scopus 로고
    • Lipidand Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials
    • Banach M, Serban C, Ursoniu S, et al.; Lipidand Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 2015; 99: 329-36.
    • (2015) Pharmacol Res , vol.99 , pp. 329-336
    • Banach, M.1    Serban, C.2    Ursoniu, S.3
  • 99
    • 42349116146 scopus 로고    scopus 로고
    • Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: Results from a crossover study
    • Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. ClinPharmacolTher 2008; 83: 731-9.
    • (2008) Clinpharmacolther , vol.83 , pp. 731-739
    • Kawashiri, M.A.1    Nohara, A.2    Tada, H.3
  • 100
    • 84908667304 scopus 로고    scopus 로고
    • Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: Arandomized clinical study
    • Skarlovnik A, Jani_ M, Lunder M, et al. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: arandomized clinical study. Med SciMonit 2014; 20: 2183-8.
    • (2014) Med Scimonit , vol.20 , pp. 2183-2188
    • Skarlovnik, A.1    Jani, M.2    Lunder, M.3
  • 101
    • 84919935151 scopus 로고    scopus 로고
    • A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy
    • Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015; 238: 329-35.
    • (2015) Atherosclerosis , vol.238 , pp. 329-335
    • Taylor, B.A.1    Lorson, L.2    White, C.M.3    Thompson, P.D.4
  • 102
    • 84920471176 scopus 로고    scopus 로고
    • Lipid and BloodPressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials
    • Banach M, Serban C, Sahebkar A, et al.; Lipid and BloodPressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015; 90: 24-34.
    • (2015) Mayo Clin Proc , vol.90 , pp. 24-34
    • Banach, M.1    Serban, C.2    Sahebkar, A.3
  • 103
    • 84928027364 scopus 로고    scopus 로고
    • Nutraceuticals in lipid-lowering treatment: A narrative review on the role of chitosan
    • Patti AM, Katsiki N, Nikolic D, Al-Rasadi K, Rizzo M. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan. Angiology 2015; 66: 416-21.
    • (2015) Angiology , vol.66 , pp. 416-421
    • Patti, A.M.1    Katsiki, N.2    Nikolic, D.3    Al-Rasadi, K.4    Rizzo, M.5
  • 104
    • 84971298472 scopus 로고    scopus 로고
    • A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
    • [Epub ahead of print]
    • Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. ClinNutr 2015 [Epub ahead of print]
    • (2015) Clinnutr
    • Serban, M.C.1    Sahebkar, A.2    Dragan, S.3
  • 105
    • 84928392457 scopus 로고    scopus 로고
    • Banach M.Lipid profile and glucose changes after supplementation with astaxanthin: A systematic review and meta-analysis of randomized controlled trials
    • Ursoniu S, Sahebkar A, Serban MC, Banach M.Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci 2015; 11: 253-66.
    • (2015) Arch Med Sci , vol.11 , pp. 253-266
    • Ursoniu, S.1    Sahebkar, A.2    Serban, M.C.3
  • 107
    • 76849117367 scopus 로고    scopus 로고
    • Lipidlowering efficacy of red yeast rice in a population intolerant to statins
    • Venero CV, Venero JV, Wortham DC, Thompson PD. Lipidlowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010; 105: 664-6.
    • (2010) Am J Cardiol , vol.105 , pp. 664-666
    • Venero, C.V.1    Venero, J.V.2    Wortham, D.C.3    Thompson, P.D.4
  • 108
    • 73149101073 scopus 로고    scopus 로고
    • Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance
    • Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105: 198-204.
    • (2010) Am J Cardiol , vol.105 , pp. 198-204
    • Halbert, S.C.1    French, B.2    Gordon, R.Y.3
  • 109
    • 36048987346 scopus 로고    scopus 로고
    • Effect of ezetimibe inpatients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin
    • Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe inpatients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
    • (2007) Curr Med Res Opin , vol.23 , pp. 2183-2192
    • Gazi, I.F.1    Daskalopoulou, S.S.2    Nair, D.R.3    Mikhailidis, D.P.4
  • 110
    • 0037504445 scopus 로고    scopus 로고
    • Ezetimibe Study Group. Effect of ezetimibeco administered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
    • Ballantyne CM, Houri J, Notarbartolo A, et al; Ezetimibe Study Group. Effect of ezetimibeco administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
    • (2003) Circulation , vol.107 , pp. 2409-2415
    • Ballantyne, C.M.1    Houri, J.2    Notarbartolo, A.3
  • 111
    • 79956099377 scopus 로고    scopus 로고
    • Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and metaanalysis
    • Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and metaanalysis. Curr Med Res Opin 2011; 27: 1191-210.
    • (2011) Curr Med Res Opin , vol.27 , pp. 1191-1210
    • Mikhailidis, D.P.1    Lawson, R.W.2    McCormick, A.L.3
  • 112
    • 84929329231 scopus 로고    scopus 로고
    • Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study
    • Chang SH, Wu LS, Lee CH, et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol 2015; 190: 20-5.
    • (2015) Int J Cardiol , vol.190 , pp. 20-25
    • Chang, S.H.1    Wu, L.S.2    Lee, C.H.3
  • 116
    • 84876724789 scopus 로고    scopus 로고
    • Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance
    • Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res ClinPract 2013; 100: 46-52.
    • (2013) Diabetes Res Clinpract , vol.100 , pp. 46-52
    • Tsunoda, T.1    Nozue, T.2    Yamada, M.3
  • 117
    • 84931411520 scopus 로고    scopus 로고
    • IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    • ** The first study to report significant reductions in CVD risk with ezetimibe/simvastatin therapy in very high-risk patients achieving even lower LDL-C levels compared with simvastatin monotherapy
    • Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-97. ** The first study to report significant reductions in CVD risk with ezetimibe/simvastatin therapy in very high-risk patients achieving even lower LDL-C levels compared with simvastatin monotherapy
    • (2015) N Engl J Med , vol.372 , pp. 2387-2397
    • Cannon, C.P.1    Blazing, M.A.2    Giugliano, R.P.3
  • 118
    • 84953425720 scopus 로고    scopus 로고
    • Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity CReactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
    • Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity CReactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation 2015; 132: 1224-33.
    • (2015) Circulation , vol.132 , pp. 1224-1233
    • Bohula, E.A.1    Giugliano, R.P.2    Cannon, C.P.3
  • 119
    • 84964013895 scopus 로고    scopus 로고
    • Clinical implications of the IMPROVE-ITtrial in the light of current and future lipidlowering treatment options
    • Nov 11. [Epub ahead of print]
    • Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-ITtrial in the light of current and future lipidlowering treatment options. ExpertOpin Pharmacother 2015 Nov 11. [Epub ahead of print]
    • (2015) Expertopin Pharmacother
    • Serban, M.C.1    Banach, M.2    Mikhailidis, D.P.3
  • 120
    • 59449103939 scopus 로고    scopus 로고
    • Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: A Markovmodel
    • Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markovmodel. Am J Cardiovasc Drugs 2008; 8: 419-27.
    • (2008) Am J Cardiovasc Drugs , vol.8 , pp. 419-427
    • Ara, R.1    Pandor, A.2    Tumur, I.3
  • 121
    • 84886854727 scopus 로고    scopus 로고
    • Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy
    • Ziada A, Schwarz UI, DeGorter MK, et al. Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. Can J Cardiol2013; 29: 1395-9.
    • Can J Cardiol2013 , vol.29 , pp. 1395-1399
    • Ziada, A.1    Schwarz, U.I.2    Degorter, M.K.3
  • 122
    • 84874292234 scopus 로고    scopus 로고
    • Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials
    • Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. ClinExpPharmacolPhysiol 2013; 40: 219-26.
    • (2013) Clinexppharmacolphysiol , vol.40 , pp. 219-226
    • Geng, Q.1    Ren, J.2    Chen, H.3    Lee, C.4    Liang, W.5
  • 123
    • 84873689744 scopus 로고    scopus 로고
    • Adverse events of statinfenofibric acid versus statin mono therapy: A meta-analysis of randomized controlled trials
    • Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events of statinfenofibric acid versus statin mono therapy: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 181-8.
    • (2013) Curr Med Res Opin , vol.29 , pp. 181-188
    • Geng, Q.1    Ren, J.2    Chen, H.3    Lee, C.4    Liang, W.5
  • 124
    • 84856219904 scopus 로고    scopus 로고
    • Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity
    • Attridge RL, Linn WD, Ryan L, et al. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J ClinLipidol 2012; 6: 19-26.
    • (2012) J Clinlipidol , vol.6 , pp. 19-26
    • Attridge, R.L.1    Linn, W.D.2    Ryan, L.3
  • 125
    • 11144239674 scopus 로고    scopus 로고
    • Reporting rate of rhabdomyolysis with fenofibrate +statin versus gemfibrozil + any statin
    • Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate +statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.
    • (2005) Am J Cardiol , vol.95 , pp. 120-122
    • Jones, P.H.1    Davidson, M.H.2
  • 126
    • 84955676391 scopus 로고    scopus 로고
    • Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy
    • Ouwens MJ, Nauta J, Ansquer JC, Driessen S. Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Curr Med Res Opin 2015: 1-13.
    • (2015) Curr Med Res Opin , pp. 1-13
    • Ouwens, M.J.1    Nauta, J.2    Ansquer, J.C.3    Driessen, S.4
  • 127
    • 80053185929 scopus 로고    scopus 로고
    • Fenofibrate: A review of its use in dyslipidaemia
    • McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011; 71: 1917-46.
    • (2011) Drugs , vol.71 , pp. 1917-1946
    • McKeage, K.1    Keating, G.M.2
  • 128
    • 64749095070 scopus 로고    scopus 로고
    • Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Scott R, O'Brien R, Fulcher G, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493-8.
    • (2009) Diabetes Care , vol.32 , pp. 493-498
    • Scott, R.1    O'brien, R.2    Fulcher, G.3
  • 129
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • ACCORD Study Group
    • ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 130
    • 80053173357 scopus 로고    scopus 로고
    • Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized control ledtrials
    • Ye J, Kiage JN, Arnett DK, et al. Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized control ledtrials. DiabetolMetabSyndr 2011; 3: 24.
    • (2011) Diabetolmetabsyndr , vol.3 , pp. 24
    • Ye, J.1    Kiage, J.N.2    Arnett, D.K.3
  • 131
  • 132
    • 84895775124 scopus 로고    scopus 로고
    • Bile acid sequestrants: Glucoselowering mechanisms and efficacy in type 2 diabetes
    • Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucoselowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep 2014; 14: 482.
    • (2014) Curr Diab Rep , vol.14 , pp. 482
    • Hansen, M.1    Sonne, D.P.2    Knop, F.K.3
  • 133
    • 84940021344 scopus 로고    scopus 로고
    • CARDIoGRAMplusC4D Consortium, Stewart AF, Samani NJ, Roberts R, Paré G. Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis
    • Ross S, D'Mello M, Anand S, Eikelboom J; CARDIoGRAMplusC4D Consortium, Stewart AF, Samani NJ, Roberts R, Paré G. Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. CircCardiovasc Genet 2015; 8: 618-27.
    • (2015) Circcardiovasc Genet , vol.8 , pp. 618-627
    • Ross, S.1    D'mello, M.2    Anand, S.3    Eikelboom, J.4
  • 134
    • 33645098531 scopus 로고    scopus 로고
    • Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review
    • Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257-73.
    • (2006) South Med J , vol.99 , pp. 257-273
    • Insull, W.1
  • 135
    • 33947124605 scopus 로고    scopus 로고
    • Safety considerations with gastro intestinally active lipid-lowering drugs
    • Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastro intestinally active lipid-lowering drugs. Am J Cardiol 2007; 99: 47C-55C.
    • (2007) Am J Cardiol , vol.99 , pp. 47C-55C
    • Jacobson, T.A.1    Armani, A.2    McKenney, J.M.3    Guyton, J.R.4
  • 136
    • 33645735636 scopus 로고    scopus 로고
    • Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
    • Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
    • (2006) Am J Cardiol , vol.97 , pp. 1198-1205
    • Bays, H.E.1    Davidson, M.2    Jones, M.R.3    Abby, S.L.4
  • 137
    • 41949100903 scopus 로고    scopus 로고
    • Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    • Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625-30.
    • (2008) Am J Cardiol , vol.101 , pp. 625-630
    • Paolini, J.F.1    Mitchel, Y.B.2    Reyes, R.3
  • 138
    • 53149118030 scopus 로고    scopus 로고
    • Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    • Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J ClinPract 2008; 62: 1959-70.
    • (2008) Int J Clinpract , vol.62 , pp. 1959-1970
    • Maccubbin, D.1    Bays, H.E.2    Olsson, A.G.3
  • 139
    • 84898899088 scopus 로고    scopus 로고
    • Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease
    • Zambon A, Zhao XQ, Brown BG, Brunzell JD. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 2014; 113: 1494-8.
    • (2014) Am J Cardiol , vol.113 , pp. 1494-1498
    • Zambon, A.1    Zhao, X.Q.2    Brown, B.G.3    Brunzell, J.D.4
  • 140
    • 84894495051 scopus 로고    scopus 로고
    • The therapeutic role of niacin in dyslipidaemia management
    • Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidaemia management. J CardiovascPharmacolTher 2014; 19: 141-58.
    • (2014) J Cardiovascpharmacolther , vol.19 , pp. 141-158
    • Boden, W.E.1    Sidhu, M.S.2    Toth, P.P.3
  • 141
    • 79959919684 scopus 로고    scopus 로고
    • Pleiotropic effects of nicotinic acid: Beyond high density lipoprotein cholesterol elevation
    • Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr VascPharmacol 2011; 9: 385-400.
    • (2011) Curr Vascpharmacol , vol.9 , pp. 385-400
    • Florentin, M.1    Liberopoulos, E.N.2    Kei, A.3
  • 142
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Investigators, A.-H.1    Boden, W.E.2    Probstfield, J.L.3    Anderson, T.4
  • 143
    • 84877299845 scopus 로고    scopus 로고
    • HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
    • HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.
    • (2013) Eur Heart J , vol.34 , pp. 1279-1291
  • 145
    • 84925259873 scopus 로고    scopus 로고
    • Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: Where do these agents stand in the approval process?
    • Bishop BM. Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process? Am J Ther 2015; 22: 147-58.
    • (2015) Am J Ther , vol.22 , pp. 147-158
    • Bishop, B.M.1
  • 147
    • 36348975228 scopus 로고    scopus 로고
    • ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 148
    • 84906096364 scopus 로고    scopus 로고
    • Highdensity lipoprotein, vascular risk, cancer and infection: A case of quantity and quality?
    • Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Highdensity lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem 2014; 21: 2917-26.
    • (2014) Curr Med Chem , vol.21 , pp. 2917-2926
    • Katsiki, N.1    Athyros, V.G.2    Karagiannis, A.3    Mikhailidis, D.P.4
  • 149
    • 84861585543 scopus 로고    scopus 로고
    • Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
    • Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
    • (2012) Prog Lipid Res , vol.51 , pp. 314-324
    • Otocka-Kmiecik, A.1    Mikhailidis, D.P.2    Nicholls, S.J.3
  • 150
    • 78549235583 scopus 로고    scopus 로고
    • Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease
    • Cannon CP, Shah S, Dansky HM, et al; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-15.
    • (2010) N Engl J Med , vol.363 , pp. 2406-2415
    • Cannon, C.P.1    Shah, S.2    Dansky, H.M.3
  • 151
    • 58649091088 scopus 로고    scopus 로고
    • Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
    • Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157: 352-360.e2.
    • Am Heart J , vol.352-360
    • Bloomfield, D.1    Carlson, G.L.2    Sapre, A.3
  • 152
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-99.
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2
  • 153
    • 84938748425 scopus 로고    scopus 로고
    • Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebocontrolled phase 2 trial
    • Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebocontrolled phase 2 trial. Lancet 2015; 386: 452-60.
    • (2015) Lancet , vol.386 , pp. 452-460
    • Hovingh, G.K.1    Kastelein, J.J.2    Van Deventer, S.J.3
  • 154
    • 84871975694 scopus 로고    scopus 로고
    • PCSK9 inhibition-a novel mechanism to treat lipid disorders?
    • Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders? Curr Pharm Des 2013; 19: 3869-77.
    • (2013) Curr Pharm Des , vol.19 , pp. 3869-3877
    • Banach, M.1    Rizzo, M.2    Obradovic, M.3
  • 155
    • 84941993216 scopus 로고    scopus 로고
    • PCSK9 inhibitors-past, present and future
    • Reiner _
    • Reiner _. PCSK9 inhibitors-past, present and future. Expert Opin Drug MetabToxicol 2015; 11: 1517-21.
    • (2015) Expert Opin Drug Metabtoxicol , vol.11 , pp. 1517-1521
  • 156
    • 84942104125 scopus 로고    scopus 로고
    • PCSK9 (Proprotein convertase subtilisin/ kexin type 9) inhibitors: Past, present, and the future
    • Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/ kexin type 9) inhibitors: past, present, and the future. Eur Heart J 2015; 36: 2415-24.
    • (2015) Eur Heart J , vol.36 , pp. 2415-2424
    • Shimada, Y.J.1    Cannon, C.P.2
  • 157
    • 84893648929 scopus 로고    scopus 로고
    • Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics
    • Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
    • (2014) Nat Rev Cardiol , vol.11 , pp. 72-74
    • Mikhailidis, D.P.1
  • 158
    • 85018197350 scopus 로고    scopus 로고
    • Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: A meta-analysis of 20 randomized controlled trials
    • Li C, Lin L, Zhang W, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015; 4: e001937.
    • (2015) J am Heart Assoc , vol.4
    • Li, C.1    Lin, L.2    Zhang, W.3
  • 159
    • 84902157271 scopus 로고    scopus 로고
    • GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab
    • Stroes E, Colquhoun D, Sullivan D, et al.; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab. J Am CollCardiol 2014; 63: 2541-8.
    • (2014) J am Collcardiol , vol.63 , pp. 2541-2548
    • Stroes, E.1    Colquhoun, D.2    Sullivan, D.3
  • 160
    • 84947965019 scopus 로고    scopus 로고
    • ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
    • Moriarty PM, Thompson PD, Cannon CP, et al.; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin-Lipidol 2015; 9: 758-69.
    • (2015) J Clin-Lipidol , vol.9 , pp. 758-769
    • Moriarty, P.M.1    Thompson, P.D.2    Cannon, C.P.3
  • 161
    • 84983160332 scopus 로고    scopus 로고
    • Langslet G, et al.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
    • Kastelein JJ, Ginsberg HN, Langslet G, et al.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36: 2996-3003.
    • (2015) Eur Heart J , vol.36 , pp. 2996-3003
    • Kastelein, J.J.1    Ginsberg, H.N.2
  • 162
    • 84921459685 scopus 로고    scopus 로고
    • TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Honarpour N, Blom DJ, et al.; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 341-50.
    • (2015) Lancet , vol.385 , Issue.9965 , pp. 341-350
    • Raal, F.J.1    Honarpour, N.2    Blom, D.J.3
  • 163
    • 84921483643 scopus 로고    scopus 로고
    • RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial
    • Raal FJ, Stein EA, Dufour R, et al.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 331-40.
    • (2015) Lancet , vol.385 , Issue.9965 , pp. 331-340
    • Raal, F.J.1    Stein, E.A.2    Dufour, R.3
  • 164
    • 84878388937 scopus 로고    scopus 로고
    • The next generation of novel lowdensity lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors
    • Shen L, Peng H, Xu D, Zhao S. The next generation of novel lowdensity lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol Res 2013; 73: 27-34.
    • (2013) Pharmacol Res , vol.73 , pp. 27-34
    • Shen, L.1    Peng, H.2    Xu, D.3    Zhao, S.4
  • 165
    • 84958604041 scopus 로고    scopus 로고
    • The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis
    • Nov 17. pii: ehv563. [Epub ahead of print]
    • Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2015 Nov 17. pii: ehv563. [Epub ahead of print]
    • (2015) Eur Heart J
    • Lipinski, M.J.1    Benedetto, U.2    Escarcega, R.O.3
  • 166
    • 84926206074 scopus 로고    scopus 로고
    • Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
    • **The first study to report significant reductions in CVD risk following evolocumab therapy
    • Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. **The first study to report significant reductions in CVD risk following evolocumab therapy
    • (2015) N Engl J Med , vol.372 , pp. 1500-1509
    • Sabatine, M.S.1    Giugliano, R.P.2    Wiviott, S.D.3
  • 167
    • 84926191670 scopus 로고    scopus 로고
    • ODYSSEY LONG TERM Investigators. Efficacy and safety ofalirocumab in reducing lipids and cardiovascular events
    • **The first study to report significant reductions in CVD risk following alirocumab therapy
    • Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. **The first study to report significant reductions in CVD risk following alirocumab therapy
    • (2015) N Engl J Med , vol.372 , pp. 1489-1499
    • Robinson, J.G.1    Farnier, M.2    Krempf, M.3
  • 168
    • 84940106915 scopus 로고    scopus 로고
    • New developments in atherosclerosis: Clinical potential of PCSK9 inhibition
    • Giunzioni I, Tavori H. New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vasc Health Risk Manag 2015; 11: 493-501.
    • (2015) Vasc Health Risk Manag , vol.11 , pp. 493-501
    • Giunzioni, I.1    Tavori, H.2
  • 169
    • 84995673240 scopus 로고    scopus 로고
    • Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
    • Nov 23. [Epub ahead of print]
    • Whayne TF Jr. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Am J Cardiovasc Drugs. 2015 Nov 23. [Epub ahead of print]
    • (2015) Am J Cardiovasc Drugs
    • Whayne, T.F.1
  • 170
    • 84902293165 scopus 로고    scopus 로고
    • Hypolipidaemic drug treatment: Yesterday is not gone yet, today is challenging and tomorrow is comingsoon; let us combine them all
    • Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is comingsoon; let us combine them all. Curr Pharm Des 2014; 20: 6350-7.
    • (2014) Curr Pharm Des , vol.20 , pp. 6350-6357
    • Athyros, V.G.1    Tziomalos, K.2    Karagiannis, A.3    Mikhailidis, D.P.4
  • 171
    • 84895548648 scopus 로고    scopus 로고
    • Lomitapide and mipomersen: Two first-inclass drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia
    • Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-inclass drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014; 129: 1022-32.
    • (2014) Circulation , vol.129 , pp. 1022-1032
    • Rader, D.J.1    Kastelein, J.J.2
  • 172
    • 84949870464 scopus 로고    scopus 로고
    • Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?
    • Athyros VG, Katsiki N, Karagiannis A. Is Targeting microRNAs the Philosopher's Stone for Vascular Disease? Curr Vasc Pharmacol 2016; 14: 88-97.
    • (2016) Curr Vasc Pharmacol , vol.14 , pp. 88-97
    • Athyros, V.G.1    Katsiki, N.2    Karagiannis, A.3
  • 173
    • 84937128430 scopus 로고    scopus 로고
    • Editorial: MicroRNAs: Potential Targets for the Treatment of Cardiovascular Disease
    • Athyros VG, Katsiki N, Karagiannis A. Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease. Curr VascPharmacol 2015; 13: 366-7.
    • (2015) Curr Vascpharmacol , vol.13 , pp. 366-367
    • Athyros, V.G.1    Katsiki, N.2    Karagiannis, A.3
  • 174
    • 84875210174 scopus 로고    scopus 로고
    • Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis
    • Mäkinen PI, Ylä-Herttuala S. Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. Curr Opin Lipidol 2013; 24: 116-22.
    • (2013) Curr Opin Lipidol , vol.24 , pp. 116-122
    • Mäkinen, P.I.1    Ylä-Herttuala, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.